Baxter International’s Novum Infusion Pump – Will the Relaunch Ignite a Revenue Surge? 

Baxter International’s second quarter 2025 earnings results portray a complex landscape of solid financial performance alongside challenges in specific sectors. Baxter reported sales from continuing operations of $2.8 billion, reflecting a growth of 4% on a reported basis and 1% on an operational basis from the prior year. However, this growth remained at the lower end of the company’s expectations, as declines in certain segments, such as the Medical Products & Therapies and Pharmaceuticals, offset the performance of other areas.